Zai Lab is a Shanghai, China-based innovative biopharmaceutical company that discovers or licenses, develops and commercializes proprietary therapeutics for the China market. Its areas of focus include oncology, autoimmune and infectious diseases, targeting large unmet medical needs. The company has assembled a pipeline of potential best-in-class and first-in-class therapeutics at different stages by securing partnerships with multinational pharmaceutical and innovative biotechnology companies. It raised US$30m in a Series C equity financing to strengthen its financial position. Zai Lab intends to use the proceeds to increase research and development efforts and to support future partnering activities. The funding is intended to advance its R&D and partnership strategies within China. Zai Lab is a Shanghai, China–based biopharmaceutical company focused on discovering, developing and commercializing a pipeline of antibody-based therapies and other protein-based therapeutics that modulate the immune system or directly target tumors. The company’s programs target patient populations with high unmet medical need, including many underserved indications specific to the Asian region. Led by founder, Chairman and CEO Dr. Samantha Du, Zai Lab pursues both internal R&D and in-licensing to build its portfolio. The company secured over $100M in Series B financing to support its research and development programs. Management intends to use the proceeds for ongoing in-licensing and commercialization efforts. Existing strategic backers include Qiming Ventures, Sequoia Capital China, TF Capital and Kleiner Perkins Caufield & Byers. ZAI Laboratory, Inc. is a Shanghai-based biopharma company that adopts a semi-virtual model to build a pipeline of five to six drug candidates. The company focuses on novel medicines in oncology, autoimmune disorders and anti-infectives and will primarily in-license assets for the China/Asia or global markets. ZAI plans to advance most programs through Phase II before partnering, and in some cases may complete clinical development itself. The team is led by CEO Dr. Samantha Du, previously founder and CEO of Hutchison MediPharma and a former healthcare investor at Sequoia Capital in China. ZAI has limited near-term staffing plans of about 50 employees and has already completed its first in-licensing deal for two Sanofi respiratory candidates with preclinical work finished. The company recently secured Series A funding to support its clinical programs and in-licensing activities.

Total raised

$160M

Funding rounds

3

Latest round

Series C

Latest activity

Jun 2017